1. Scrip
  2. >>Therapy Areas
  3. >>Cardiovascular

Kitov Plans 2016 NDA For Arthritis Combo Drug

 
• By Mandy Jackson

Kitov Pharmaceuticals, which went public in the US in November, ended Dec. 15 with a 25.2% stock price gain at $4.47 per share based on positive Phase III results for lead drug candidate KIT-302 and the Israeli company's plans to seek US FDA approval for the treatment of osteoarthritis.

Kitov Pharmaceuticals, which went public in the US in November, ended Dec. 15 with a 25.2% stock price gain at $4.47 per share based on positive Phase III results for lead drug candidate KIT-302 and the Israeli company's plans to seek US FDA approval for the treatment of osteoarthritis.

KIT-302 combines Pfizer Inc.'s former blockbuster and now generic non-steroidal anti-inflammatory drug (NSAID) Celebrex (celecoxib) with the calcium channel blocker...

Welcome to Scrip

Create an account to read this article

Already a subscriber?

More from Cardiovascular

Novartis Upbeat Even With Entresto Expiry Looming

 
• By Kevin Grogan

Swiss major confident that new oncology drugs will fill revenue gap.

AstraZeneca’s Amyloidosis Drug Fails In Phase III But Subgroup Hopes Persist

 
• By Andrew McConaghie

Anselamimab was expected to complement Alexion's portfolio of amyloid therapies, but regulators will have to be convinced of its benefits to a patient subgroup in the CARES trial.

Bayer’s Kerendia Gains Blockbuster Indication For Heart Failure

 
• By Joseph Haas

New US approval in heart failure with preserved or mildly reduced ejection fraction should add to Kerendia’s earning power on top of chronic kidney disease indication.

Phase III Success For AstraZeneca’s $5bn Hypertension Hope Baxdrostat

 
• By Andrew McConaghie

Rivals Mineralys could be first to file but AstraZeneca is banking on its cardiovascular market know-how to lead the emerging class.

More from Therapy Areas

BMS/Pfizer To Sell Discounted Eliquis Direct – And Other Drugmakers May Follow Suit

 
• By Alaric DeArment

Analysts see the new strategy as a way to address pressure from the Trump administration’s most favored nation drug pricing proposals.

Actuate Is Looking For A Buyer To Advance Pancreatic Cancer Candidate

 
• By Jessica Merrill

After presenting encouraging Phase II data on the GSK-3 inhibitor elraglusib at ASCO, Actuate Therapeutics is hoping to hold a pre-NDA meeting with the US FDA.

Novartis Upbeat Even With Entresto Expiry Looming

 
• By Kevin Grogan

Swiss major confident that new oncology drugs will fill revenue gap.